Debate continues as to whether the detection of herpes simplex virus (HSV) in lower respiratory tract specimens, especially from immunosuppressed, critically ill patients, and organ transplant recipients, represents a true clinical infection requiring therapy or innocuous viral shedding secondary to severe underlying illness.
Debate continues as to whether the detection of herpes simplex virus (HSV) in lower respiratory tract specimens, especially from immunosuppressed, critically ill patients, and organ transplant recipients, represents a true clinical infection requiring therapy or innocuous viral shedding secondary to severe underlying illness. [1] [2] [3] [4] Moreover, rendering a confident clinical diagnosis of HSV pneumonia is challenging, particularly because many patients lack easily detectable herpetic lesions, radiographic and bronchoscopic findings are nonspecific, and clinical interpretations are frequently complicated by superimposed coinfections. [5] [6] [7] [8] The morphologic and immunohistochemical evaluation of cellular material for the cytopathic effect of HSV, using bronchoalveolar lavage (BAL) cytology or lung biopsy specimens performed for another reason, constitutes the gold standard for HSV diagnosis due to the high specificity, but suffers from poor sensitivity. 9 In many medical centers, the preferred method for identifying HSV in BAL specimens has become viral culture. Conventional viral culture, however, has a lengthy turnaround time (TAT) and is thus not the ideal diagnostic modality for guiding therapeutic decisions in critically ill patients.
Detection of HSV in the lower respiratory tract is further complicated by the nonuniformity of lavage specimens. BAL cellularity is affected by environmental exposures and underlying disease, as well as operator experience and technique. [10] [11] [12] Unlike HSV viremia, where the diagnosis is
In this study, we determined a quantitative threshold of HSV DNA in lower respiratory tract specimens that correlated with positive viral culture and clinical outcome. We also investigated the utility of quantitative polymerase chain reaction (qPCR) for a housekeeping gene to account for differences in the cellularity of the lower respiratory tract specimens. Finally, we evaluated the relationship between the HSV viral load and clinically relevant outcomes.
Materials and Methods

Study Population
This retrospective study was approved by the University of Pittsburgh Institutional Review Board. The University of Pittsburgh Medical Center (UPMC) Clinical Microbiology Laboratory database was queried for data from January 1, 2014, to December 31, 2016, for viral cultures performed on lower respiratory tract specimens in patients age 18 years or older. Matched culture-negative controls were selected based on age, sex, race, organ transplant status, intensive care unit (ICU) status, and mechanical ventilation support. Medical records were reviewed to determine the source of admission, immune status, comorbidities, coinfection with viral, bacterial, or fungal respiratory pathogens, antiviral treatment, bronchoscopic and radiologic findings, and mortality.
Viral Culture
Lower respiratory tract specimens submitted to the microbiology laboratory were processed for viral, bacterial, and fungal cultures as clinically indicated using routine microbiological methods. Viral culture included evaluation for HSV, cytomegalovirus, and varicella zoster virus. BAL and bronchial wash (BW) specimens were collected in sterile containers and received in the microbiology laboratory as a single 10-mL to 20-mL unprocessed sample. Viral tube culture was performed by inoculating 0.25 mL of specimen onto an A549 and MRHF cell monolayer (Diagnostic Hybrids, Athens, OH). The viral cultures were maintained at 37°C with specimen media changed once per week. HSV cytopathic effect (CPE), defined as focal clusters of rounded ballooned cells, was assessed every other day for 3 weeks starting on the day after inoculation.
Confirmation of the CPE was performed, as indicated, by staining with HSV-specific monoclonal antibody (Trinity MicroTrak HSV 1/HSV 2 Culture Identification/Typing Test; Trinity Biotech, Jamestown, NY).
Other Microbiological Diagnostic Methods
Clinical cytology and lung biopsy reports were reviewed for the presence of viral inclusions, fungal organisms, and background inflammation. Cytology specimens were assessed for an HSV viral cytopathic effect by the primary pathologist at the time of initial diagnosis, at which time the decision to perform special stains for HSV was made at the discretion of the primary pathologist. This study reviewed completed cytology reports and did not involve reassessment of the cytology specimens themselves, nor were additional stains requested on the specimens for the purpose of this study. Immunohistochemistry for HSV was performed by automated staining on the Leica Bond III (Leica Biosystems, Buffalo Grove, IL) using anti-HSV-1/-2 polyclonal rabbit antibodies (BioLegend, San Diego, CA).
All BAL specimens in this study underwent routine micrologic workup at time of collection, including bacterial culture with Gram stain when appropriate, and a nucleic acid-based respiratory viral panel (RVP; Genmark Diagnostics, Carlsbad, CA) for the detection of influenza AH1, influenza AH3, influenza B, influenza 2009 H1N1, respiratory syncytial virus (RSV) A, RSV B, parainfluenza (PIV) 1, PIV 2, PIV 3, metapneumovirus, rhinovirus, adenovirus B/E, and adenovirus C.
Quantitative PCR
All in-house testing was performed under the policies and procedures for clinical testing in a Clinical Laboratory Improvement Amendments-certified laboratory at UPMC. Cryopreserved BAL and BW specimens positive for HSV culture, along with matched culture-negative controls, were retrieved from the laboratory archives. A 200-µL aliquot of sample was incubated with proteinase K for 1 hour at 56°C. Phocine herpes virus (2 µL) was added to each sample as an internal positive control (IPC) to assess for extraction efficiency and PCR inhibition. DNA extraction was performed using the NucliSENS easyMAG automated extraction system (bioMerieux, Durham, NC) according to the manufacturer's recommendations. Purified DNA was eluted in 100 µL of elution buffer and stored at −20°C until further use. qPCR for HSV-1, HSV-2, IPC, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were performed in separate reactions, as outlined below, using a single nucleic acid extract.
To determine the absolute copy number of HSV-1 and HSV-2 in the samples, quantitative real-time PCR using primers directed against the thymidine kinase (TK) gene was performed using a standard consisting of quantified plasmid (ZeptoMetrix, Buffalo, NY) containing the PCR target. Amplification of HSV-1 and HSV-2 targets were performed in 25-µL reactions using the LightCycler (Roche, Indianapolis, IN) and TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA) under the following cycling conditions: 2 minutes at 50°C, followed by 10 minutes at 95°C and 45 cycles of 10 seconds at 95°C and 30 seconds at 68°C. The absolute copy number/mL (viral load) was determined using the standard curve and expressed as the viral copy number per mL of BAL. Specimens with viral loads above the upper limit of quantification (1.1 × 10 6 ) were repeated using higher calibration standards (up to 10 8 copies/mL) for accurate viral load quantification. The limit of detection (LOD) and lower limit of quantification (LLOQ) for HSV-1 and HSV-2 was 200 and 400 copies/mL, respectively.
To assess whether controlling for lavage cellularity improved the correlation between HSV viral load and viral culture or clinical outcomes, the HSV copy number in each sample was normalized to the qPCR detected level of the housekeeping gene GAPDH in the sample. The normalized qPCR result was expressed as HSV copy number per 10 4 copies of GAPDH. 13, 14 Low cellularity specimens were identified as those having a GAPDH copy number lower than three standard deviations below the mean GAPDH copy number for all specimens.
The primers and probes for all targets are described in Supplemental Table 1 (all supplemental materials can be found at American Journal of Clinical Pathology online). Viral culture-qPCR discrepant samples underwent confirmatory testing performed at Viracor (Eurofins Viracor, Lee's Summit, MO) using qPCR directed against the HSV-1 and HSV-2 glycoprotein G region with a reported LLOQ of 58 and 248 copies/mL, respectively.
Statistical Analysis
Statistical analyses were performed using Stata version 14 (StataCorp, TX). An independent samples t test and a Mann-Whitney U test were used to compare normally and nonnormally distributed continuous variables, respectively. Fisher exact test or a χ 2 test was used to compare count data and ratios, where appropriate.
The combined clinical outcome was defined a priori as a combination of the following clinically relevant individual outcomes: (1) death within 21 days after specimen collection; (2) length of stay more than 21 days after sample collection; and/or (3) ICU stay for more than 14 days after sample collection.
Receiver operating characteristic (ROC) curves were generated using viral culture or the combined clinical outcome as the binary dependent variable for determining the HSV-1 viral loads that corresponded with maximum diagnostic accuracy (Youden method). Regression analysis was used to assess the relationships between HSV-1 viral load and TAT for HSV-positive viral culture results (Poisson regression) and between HSV-1 viral load and clinically relevant outcomes (logistic regression). Both clinical and statistical significance (alpha level of 0.10) were considered in the decision to include independent variables into the bootstrapped multivariate logistic regression models. 15 Cox proportional hazards analysis was performed to compare the event-free survival for clinical outcomes stratified by the HSV qPCR results.
Results
Patient Demographics, Clinical Features, and Radiographic/Bronchoscopic Findings
Among 4,924 BAL/BW archived samples submitted to the clinical laboratory for viral culture over the 3-year period, 68 HSV-1-positive specimens from 62 unique patients were identified. We analyzed 42 BAL and 11 BW specimens from 53 unique patients by HSV-1 and HSV-2 qPCR after exclusion of duplicate samples (n = 7) and those that had insufficient volume (n = 6) or failed PCR amplification (n = 2). qPCR analysis was also performed on the matched culture-negative controls (n = 61). Most patients were immunosuppressed, and approximately 40% were transplant recipients. More than two-thirds of the specimens were collected from ICU patients, with the majority receiving mechanical ventilation at the time of specimen collection ❚Table 1❚. Patients with HSV-positive cultures were significantly more likely to have received mechanical ventilation for at least 48 hours prior to specimen collection compared with matched controls (Table 1) . Coinfections in the week preceding and at the time of viral culture specimen collection (Supplemental Table 2 ), as well as radiographic, bronchoscopic, and cytologic findings ❚Table 2❚, were not significantly different between the HSV viral culture-positive and -negative groups. Of note, more patients with negative HSV viral cultures received prophylactic antiviral therapy prior to specimen collection ( Table 2) .
Comparison of HSV qPCR With Viral Culture for Identification of HSV-1
Empirical threshold estimation identified an optimal HSV-1 qPCR threshold of 1.62 × 10 3 copies/mL for classification of viral culture (Youden index, J: 0.854), with a corresponding positive and negative percent agreement of 95.9% and 90.8%, respectively.
There were nine specimens with culture-qPCR discrepancies. Samples from four patients were culture negative but tested positive by the in-house and reference laboratory HSV-1 qPCR methods ❚Table 3❚. Of these discrepant cases, two patients were negative for bacterial, fungal, or other viral pathogens in the diagnostic BAL sample, but had clinical and radiologic findings consistent with pneumonia, and another patient received acyclovir on the day of specimen collection and 2 days prior for systemic HSV infection. There were four culture-positive samples that were negative for HSV-1 by qPCR by both the in-house and reference methods.
Although the reason for the discrepancy in these samples is not well defined, other viruses (RSV and enterovirus) were detected in two of these culture-positive specimens using GenMark's RVP. A fifth culture-positive discrepant sample contained an HSV-1 viral load of 700 copies/mL per the reference laboratory's assay but was negative (below the LOD) using the in-house HSV qPCR assay; this sample was also positive for adenovirus using the RVP.
Based on the agreement between two diagnostic methods for the detection of HSV (culture and PCR or two PCR methods with different targets), HSV qPCR had a sensitivity and specificity of 98.0% and 100%, respectively, compared to a sensitivity and specificity of 92.5% and 93.4%, respectively, for HSV viral culture.
Turnaround Time
The median TAT for viral culture was 21.8 days (IQR: 20.9-22.8 days) for culture-negative specimens and 9.9 days (IQR: 6.3-12.9 days) for culture-positive specimens (P < .001; ❚Figure 1A❚). The HSV-1 DNA copy number correlated poorly with the length of time to positive viral culture (pseudo-R 2 = 0.0712; ❚Figure 1B❚).
Correlation With Clinical Outcomes and Patient Management
The presence of a positive HSV viral culture alone was not a predictor of a worse combined clinical outcomes (67.9% of viral culture-positive cases and 63.9% of matched viral culture-negative controls met the combined clinical outcome, P = .654).
Empirical estimation identified an optimal HSV-1 qPCR threshold of 1.3 × 10 4 copies/mL for classification of the combined clinical outcome, with a corresponding positive predictive value of 80.5% and a negative predictive value of 48.0%. Individual and combined clinical outcomes based on the above HSV-1 qPCR thresholds were compared for all patients ❚Table 4❚. Patients with HSV viral loads equal to or greater than 1.3 × 10 4 copies/ mL had a significantly longer median length of hospital stay after specimen collection compared to those with viral loads less than 1.3 copies/mL (P = .027).
Using an HSV-1 viral load threshold of equal to or greater than 1.3 × 10 4 copies/mL, the HSV qPCR result (odds ratio [OR] = 2.68, P = .093) and presence of radiographic findings of pneumonia (OR = 8.52, P < .001) were the only significant predictors of a worse combined clinical outcome in the multivariate logistic regression model (pseudo-R 2 = 0.21). Age, presence of respiratory comorbidities, coinfections in the same specimen, transplant status, and immunosuppression were not significant predictors of worse clinical outcome. In the Cox regression models for survival without meeting the combined clinical outcome, that is event-free survival, patients with an HSV-1 viral load equal to or greater than 1.3 × 10 4 copies/mL had a worse outcome compared to those patients with viral load less than 1.3 × 10 4 copies/ mL (hazard ratio [HR] = 4.27, P = .017; ❚Figure 2❚) and there was also a trend of worse clinical outcome in those with high HSV-1 viral load compared to those patients with undetectable HSV-1 (HR = 1.60, P = .056; Figure 2 ).
Most patients (73.2%, 30/41) with high HSV-1 viral load (≥1.3 × 10 4 copies/mL) also had radiographic findings consistent with pneumonia; however, only 40% (12/30) of these patients had evidence of other pulmonary pathogens in the diagnostic BAL/BW specimen. In patients with detectable but low HSV-1 viral loads (<1.3 × 10 4 copies/mL), 63.6% (7/11) had radiographic evidence of pneumonia and 57.1% (4/7) of these patients also had evidence of other pulmonary pathogens. In those with undetectable HSV-1 by qPCR, 56.5% (35/62) had radiographic evidence of pneumonia and 57.1% (20/35) of these patients also had evidence of other pulmonary pathogens. Twenty-one viral culture-positive patients (39.6%) received antiviral treatment after the culture results were available (median, 13 days; range, 2-31 days from sample collection to therapy initiation). Twenty-two patients, 20 of whom were transplant recipients, received prophylactic antiviral therapy with acyclovir or valganciclovir prior to and following BAL collection (five culture-positive and 17 culture-negative). In addition, four culture-positive patients and five controls were treated before culture results were available, due to clinical suspicion of HSV infection.
Clinical Utility of Normalization With GAPDH
Median GAPDH levels of HSV viral culture-positive and -negative specimens were similar (Table 2 ). Only three specimens had a GAPDH copy number more than three standard deviations below the mean for all specimens, Combined clinical outcome includes death within 21 days after specimen collection, length of stay more than 21 days after sample collection, and ICU stay for more than 14 days after sample collection.
indicating low sample cellularity. Apart from seven outliers (Cook's distance greater than three times the mean Cook's distance), there was excellent agreement between the log 10 HSV result and the log 10 -normalized HSV result (adjusted R 2 : 0.57 and 0.92 with and without outliers, respectively; ❚Figure 3A❚). For all seven outliers, the HSV viral culture was positive, and the log 10 -normalized HSV result was higher than the result predicted by the regression line. When using viral culture as the reference method, there was no significant difference between the area under the curve (AUC) for the nonnormalized and normalized HSV results (0.936 vs 0.937, P = .270; ❚Figure 3B❚). Likewise, for the combined clinical outcome, there was no significant difference in the AUC for the nonnormalized and normalized HSV results (0.599 vs 0.610, P = .258).
Discussion
The significance of identifying HSV in the lower respiratory tract is controversial. 16, 17 Moreover, making a definitive diagnosis of HSV-1 infection or pneumonia remains challenging due to the lack of a gold standard test and the fact that cytologic changes are specific, but insensitive, markers of HSV infection. Nonetheless, given its potential role as a clinically significant pathogen, many laboratories offer viral culture as a means to detect HSV in BAL and BW samples. Although culture detects live replicating virus that is more consistent with acute infection rather than colonization or shedding, it has limited clinical utility due to a prolonged TAT. HSV-positive patients are predominantly critically ill or immunosuppressed and require a rapid diagnostic test to help guide treatment decisions. 18, 19 The results of this study support the use of a validated HSV DNA qPCR assay as an alternative to viral culture for rapidly detecting HSV in lower respiratory tract samples. Utilizing ROC analysis, we identified an optimal HSV-1 viral load threshold of 1.62 × 10 3 copies/ mL for discriminating between positive and negative viral culture results. The results of the in-house PCR were in agreement with 93% of culture results. Adjudication of the nine culture-qPCR discrepant samples based on testing by another nucleic acid amplification tests performed at a reference laboratory indicated an agreement between the two qPCR assays and suggested that culture may have provided false-negative or -positive results in eight out of nine cases (Table 3) . For the culture-positive discrepant cases, the subjectivity of CPE determination without confirmatory testing in all cases, particularly in the presence of other viruses identified by RVP, may have resulted in false-positive identification of HSV by viral culture. 20 Prior research has identified a putative relationship between elevated HSV viral load and increased mortality, with described viral load thresholds ranging from greater than 10 4 to equal to or greater than 10 5 HSV copies/mL. [21] [22] [23] [24] This study assessed the relationship between HSV-1 viral loads and a composite outcome measure comprising clinically relevant outcomes of death within 21 days after sample collection, ICU stay for more than 14 days after collection, and/or hospital stay for more than 21 days after collection. This study also assessed outcomes in an HSV viral culture-negative control cohort, which was matched for important characteristics that ❚Figure 2❚ Kaplan-Meier curves for event-free survival, that is, without meeting one of the following clinical outcomes: death within 21 days after specimen collection, length of stay more than 21 days after sample collection, and/or intensive care unit stay for more than 14 days after sample collection. A herpes simplex virus (HSV) viral load ≥1.3 × 10 4 copies/mL was associated with worse event-free survival compared to those with a viral load <1.3 × 10 4 copies/mL (hazard ration [HR] = 4.27, P = .017). P < .05. HR and P values were derived using univariate Cox maximum likelihood, proportional hazards models after testing the proportionality hazards assumption. LOD, limit of detection. 4 copies/mL) had a significantly worse combined clinical outcome. There was also a trend of higher mortality in patients with high HSV-1 qPCR viral load (≥1.3 × 10 4 copies/mL) compared to those with undetectable HSV-1 by qPCR. Clinical outcomes were worst in those patients with radiographic findings indicative of pneumonia, and many patients (60%) with both high HSV-1 viral loads and radiographic evidence of pneumonia did not have evidence of other pulmonary pathogens in their BAL/BW specimen. Given the high sensitivity of culture for the diagnosis of bacterial pneumonia, this latter finding suggests that infection with HSV-1 may have been the cause of the radiographic changes and worse clinical outcome. 25 It is well documented that the analytical sensitivity of qPCR varies based on sample cellularity.
14 Therefore, in this study, we normalized the HSV-1 viral load to the level of a housekeeping gene, GAPDH, to control for variability in bronchoscopic sampling technique, bronchial tree collection site, lavage volume, and operator experience. [26] [27] [28] The results, in general, show an excellent correlation between the normalized and nonnormalized HSV results and provide little support for normalization of HSV viral loads in BAL/BW specimens using a housekeeping gene. The incidence of very low cellularity specimens in this study, determined by comparing the GAPDH levels in all specimens analyzed across three different specimen runs or batches, was rare (three out of 114 specimens). However, larger cohorts would need to be assessed to evaluate whether there is a more significant variability in bronchial specimen cellularity and whether the use of a housekeeping gene for identification of low cellularity specimens is warranted.
The findings of this study should be interpreted in the context of a few recognizable limitations, mainly the single-center retrospective case-control design and the relatively low power to detect small differences in outcome associated with high HSV viral load. In addition, a known limitation of DNA qPCR is that it does not provide information regarding viral pathogenic activity, although a high viral load is more likely consistent with replicating virus. Thus, the HSV-1 qPCR assay is best utilized in conjunction with a strong suspicion for pneumonia based on clinical and radiographic evidence. In such a setting, it may assist clinicians with managing critically ill and transplant patients with negative bacterial cultures, fungal cultures, and respiratory virus panels. Definitive confirmation of the role of HSV-1 as a cause of pneumonia and the role of promptly initiated antiviral therapy will require larger patient cohorts and, likely, a multicenter study due to the low incidence of HSV in BAL/BW specimens at this institution.
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❚Figure 3❚ A, Scatterplot of log 10 -normalized herpes simplex virus (HSV) result vs log 10 HSV result. Apart from seven outliers (filled circles) identified as having a Cook's distance greater than three times the average Cook's distance, there was excellent agreement between the log 10 HSV copies/mL result and the log 10 -normalized HSV result (adjusted R 2 , 0.57 and 0.92 with and without outliers, respectively, using linear regression). For all seven outliers, the HSV viral culture was positive and the log 10 -normalized HSV result was higher than the result predicted by the regression line. B, Receiver operating curve analysis using viral culture as the reference method. There was no significant difference in the area under the curve for the log 10 -normalized HSV result (0.938, 95% confidence interval [CI]: 0.891-0.985) compared to the HSV copy number without normalization (0.936, 95% CI: 0.887-0.984, P = .270). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Finally, cytology specimens were not reassessed for the presence of an HSV viral cytopathic effect, nor were additional immunohistochemistry studies for HSV requested if they had not been performed during the initial workup. Notably, a cytologic diagnosis of HSV infection was only made in approximately 6% of samples positive for HSV by qPCR during the initial diagnostic workup. Further, there was no difference in bronchoscopic findings between HSV viral culture-positive and viral culture-negative patients. Thus, while it is possible that the diagnosis of HSV infection in the lower respiratory tract could have been missed by cytology and/or bronchoscopy only, this would most likely be attributable to the low sensitivity of these methods and not due to errors in the initial diagnostic workup.
In conclusion, HSV qPCR has clinical utility for the rapid and accurate identification of HSV-1 in lower respiratory tract specimens with a superior TAT compared to viral culture and a higher sensitivity than cytologic evaluation. Indeed, utilization of HSV qPCR may eliminate the need to perform less-sensitive diagnostic modalities for HSV in a patient with suspected HSV pneumonia. In addition, a high HSV-1 viral load was associated with worse clinical outcomes compared to patients with low HSV-1 viral loads. Whether the rapid initiation of antiviral therapy based on qPCR results alters the clinical course of patients with HSV-1 in their lower respiratory tract remains to be determined in larger prospective studies. 
